Form 4: United Therapeutics COO Sells Shares Under 10b5-1 Plan

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned sales of common stock totaling 22,500 shares on October 6, 2025, following option exercises.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), reported transactions on October 6, 2025.
• The transactions involved the exercise of stock options and subsequent sale of common stock, executed pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
• Acquired 14,625 shares by exercising stock options at $135.42 per share.
• Acquired an additional 7,875 shares by exercising stock options at $146.03 per share.
• Sold a total of 22,500 shares of common stock across multiple transactions.
• Sale prices for the common stock ranged from approximately $253.975 to $454.81 per share, with weighted average prices provided for various blocks.
• Beneficial ownership of common stock in the trusts involved in these specific transactions decreased to 0.00.
• An additional 2,648 shares of Common Stock were disposed of directly.
• Remaining derivative securities include 99,750 stock options (exercisable from March 15, 2023, expiring March 15, 2027) and 17,500 stock options (exercisable from March 15, 2018, expiring March 15, 2027).

Sentiment

Score: 5

Explanation: Neutral. The filing reports pre-planned insider transactions (option exercise and sale) which are routine for executives managing their equity compensation. It doesn't indicate positive or negative company performance, but rather personal financial planning.

Positives

• Officer monetized vested equity at significantly higher prices than option exercise costs, indicating personal financial gain.
• Transactions were pre-planned under a Rule 10b5-1 plan, suggesting a structured approach to equity management rather than a reaction to immediate company news.

Negatives

• Significant insider selling by a high-ranking executive, even if pre-planned, can sometimes be perceived negatively by the market.
• The reporting person's direct beneficial ownership of common stock decreased to 0.00 in the trusts involved in these specific transactions.

Risks

• No specific risks beyond the general market perception of insider selling are mentioned in this Form 4.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4, which is primarily a disclosure of insider transactions.

Industry Context

This filing is a routine insider transaction disclosure and does not provide information to analyze broader industry trends or competitors. It reflects an executive's personal financial planning.

Comparison to Industry Standards

• This filing does not contain information that allows for a comparison to global benchmarks or specific comparable companies/projects. It is a disclosure of personal stock transactions by an executive.

Related Party Transactions

• The transactions involve trusts where the reporting person and/or family members are beneficiaries and co-trustees, which are standard disclosures for executive compensation and beneficial ownership.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a signal, though the 10b5-1 plan mitigates immediate negative implications. It provides transparency into executive compensation monetization.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

While the filing reports significant insider selling by a high-ranking executive, these transactions were executed under a pre-arranged Rule 10b5-1 trading plan. This suggests a systematic approach to managing equity compensation rather than a reaction to new, adverse company information. Therefore, it does not inherently signal a change in the company's fundamental outlook, warranting a 'hold' recommendation based solely on this filing, pending further fundamental analysis.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Executive Compensation, Share Sale